α-Terpineol: Pregnancy Fragrance Safety in 2025 Study

Introduction

Evidence on fragrance exposure during pregnancy remains limited, with much of the data derived from animal studies. A 2025 toxicology investigation on α-terpineol, a common monoterpene alcohol, reported reproductive effects in male rats at high doses. This finding aligns with broader safety assessments for individual fragrance materials, emphasizing the importance of exposure context and distinguishing between hazard identification and real-world risk.

α-Terpineol Study Shows Dose-Dependent Effects in Rats

In May 2025, researchers from Vijayanagara Sri Krishnadevaraya University published new data on α-terpineol. Hegde and Malashetty administered the compound orally to Wistar rats at doses of 0, 75, 150, and 300 mg/kg/day. No adverse effects were observed at 75 mg/kg/day, but effects emerged at 150 mg/kg/day and intensified at 300 mg/kg/day.

Male rats exhibited inhibited body weight gain, reduced food intake, and azoospermia. Serum testosterone levels dropped significantly, and histopathological examination revealed damage to testis and epididymis tissue. The study also noted decreased serum thyroxine (T4) levels in both adult males and pregnant females at the two higher doses, without a corresponding change in thyroid-stimulating hormone (TSH). The authors concluded that α-terpineol induced reproductive toxicities in male rats, recommending further toxicological assessment. Importantly, the doses used vastly exceed typical human exposure from fragrance.

RIFM Safety Assessments Provide a Framework for Risk

Individual studies are interpreted within a broader safety evaluation system. The Research Institute for Fragrance Materials (RIFM) employs a panel of external experts to assess ingredients. A 2022 assessment for 6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-propionaldehyde exemplifies this process.

RIFM’s assessment reviews existing data on a material’s genotoxicity, repeated dose toxicity, reproductive toxicity, and environmental fate. For reproductive toxicity, the process involves analyzing all available animal studies, applying uncertainty factors to account for species and individual differences, and deriving a safe exposure level. This calculated safe level is then compared with the estimated systemic exposure from all cosmetic and product uses to determine safe usage limits.

Hazard Versus Risk in Pregnancy and Formulation

The α-terpineol study highlights the distinction between hazard and risk. A hazard is a substance’s intrinsic potential to cause harm, while risk is the probability of harm under specific exposure conditions. The rat study identifies α-terpineol as a hazard to male reproduction at high oral doses.

Human risk from fragrance ingredients, however, is typically low. Systemic exposure from dermal application or inhalation in consumer products is orders of magnitude lower than the doses used in the rat study. Additionally, exposure routes differ; gavage in rats does not replicate the dermal absorption or inhalation patterns of perfume use. Formulators must consider final product concentration, frequency of use, and application area. For products marketed for use during pregnancy or baby care, adherence to the strictest International Fragrance Association (IFRA) standards is essential.

Practical Applications for Perfumers and Chemists

Formulators should adopt a science-led, evidence-based approach. First, rely on the safety conclusions of expert bodies like RIFM, which form the basis for IFRA Standards. These standards account for sensitive populations. Second, consider the product format and potential for exposure. A leave-on body lotion has a different exposure profile than a rinse-off dish soap or a gel air freshener.

Third, leverage formulation technology to manage delivery. Encapsulation systems can control release, potentially reducing initial exposure while prolonging scent. Fourth, maintain transparency with clients and consumers. While evidence for harm from typical fragrance use in pregnancy is not established, providing clear ingredient information supports informed choice.

Conclusion

Current evidence on fragrance and pregnancy primarily consists of high-dose animal studies identifying hazards, such as the 2025 α-terpineol research, and systematic human safety assessments from RIFM. For the fragrance industry, responsible practices involve strict adherence to established safety standards, thoughtful application of formulation science to manage exposure, and clear communication based on available toxicological data.

Sources:
https://pubmed.ncbi.nlm.nih.gov/39411849/
https://pubmed.ncbi.nlm.nih.gov/34742791/
https://pubmed.ncbi.nlm.nih.gov/32692847/